Evidence map›Paper›PMID 40501575›Full record

ArticlebioRxiv : the preprint server for biology2025

eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules.

Stephen C Purdy, Kate Matlin, Christopher Alderman, Amber Baldwin, Natasha Shrivastava, Somnath Dutta, Kristofor J Webb, Arthur Wolin, Dillon P Boulton, Jyoti Kapali and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Stephen C PurdyDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Kate MatlinDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0002-4011-7858
Christopher AldermanDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Amber BaldwinDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0002-7346-3052
Natasha ShrivastavaDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Somnath DuttaDepartment of Chemistry, University of Colorado, Boulder, CO, USA.
Kristofor J WebbDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, USA.
Arthur WolinDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0003-1881-390X
Dillon P BoultonDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0002-7781-3101
Jyoti KapaliDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-2855-2862
John D LanduaDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Michael T LewisDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
M Cecilia CainoDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0001-8294-8070
James C CostelloDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0003-3158-9682
William OldDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, USA.ORCID 0000-0002-9499-8478
Xiang WangDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Rui ZhaoCancer Biology Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Heide L FordDepartment of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0002-2860-9841
Neelanjan MukherjeeDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.ORCID 0000-0003-0017-1400

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael T. Lewis · 2007 to 2026
$73.9M
The molecular mechanism of pre-mRNA splicingR35GM145289 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI RUI ZHAO · 2022 to 2026
$4.3M
Training in Translational Research of Lung, Head and Neck CancerT32CA174648 · NCI · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2013 to 2022
$4.2M
Predoctoral Training Program in Molecular and Cellular Biology (Supplement: Mentoring in the Research Environment)T32GM136444 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MICHAEL A MCMURRAY, Rytis Prekeris · 2020 to 2026
$3.7M
Training Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5M
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate MetastasisR01CA224867 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., LEWIS, MICHAEL T. · 2019 to 2023
$3.2M
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progressionR01CA221282 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., ZHAO, RUI · 2017 to 2021
$3.2M
Temporal coordination of stimulus-induced gene expression by RNA-binding proteinsR35GM147025 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Neelanjan Mukherjee · 2022 to 2026
$1.9M
NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA221282NCI NIH HHS R01 CA224867NCI NIH HHS T32 CA174648NCI NIH HHS T32 CA190216NIGMS NIH HHS R35 GM145289NIGMS NIH HHS R35 GM147025NIGMS NIH HHS T32 GM136444
6 · The paper itself

Abstract

Exposure to hypoxia is linked to increased cellular plasticity and enhanced metastasis; effects which are primarily attributed to the transcriptional activation of large gene programs downstream of hypoxia inducible factors (HIFs). However, translational effects in hypoxia, that likely precede transcriptional effects, have remained largely unexplored. Using ribosome-profiling, we uncovered a selective translational response in acute hypoxia that is eIF3d/eIF3e-dependent and controls downstream hypoxic responses including HIF1a accumulation and cellular invasion. We further demonstrated that eIF3e copy number and an eIF3e-expression signature are associated with worsened outcomes for breast cancer patients. Finally, we identified a class of novel small molecules that target eIF3e specifically, reducing the translational response to hypoxia and to ER stress, another stressor that is dependent on eIF3d/eIF3e-mediated translation. Our data uncover critical functions for eIF3d/eIF3e in the hypoxic response and identify a potential means to inhibit stress-induced translation, and potentially plasticity and metastasis, mediated by eIF3e.

Identifiers

PMID40501575
PMCPMC12154685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.